

Gliclazide

for the treatment of type 2 diabetes mellitus

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

Following an evaluation of gliclazide for the treatment of type 2 diabetes mellitus, gliclazide 80mg immediate release tablet is recommended for listing on the MOH Standard Drug List 1 (SDL1) by the MOH Drug Advisory Committee in view of its better safety profile compared to other sulfonylureas and low annual cost of subsidy.

This recommendation means that subsidies will apply to gliclazide 80mg immediate release tablet for the indications registered in Singapore:

 Non-insulin-dependent diabetes, in association with an adapted diet, in cases where dietary measures alone provide inadequate control of blood glucose levels.

Gliclazide 60mg modified release tablet is not recommended for listing on the MOH Standard Drug List in view that there is no difference in clinical outcomes for the modified release tablet compared with the immediate release tablet to justify the significant cost difference between the two preparations.

Published on 3 May 2017



About the Agency

The Agency for care effectiveness (ACE) is the national health technology assessment agency in Singapore residing within the Ministry of Health. It conducts evaluations to inform the subsidy of treatments, and produces guidance on the appropriate use of treatments for public hospitals and institutions in Singapore. When using the guidance, the responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <u>www.ace-hta.gov.sg/about</u>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Application to reproduce any part of this publication should be addressed to:

Head (Evaluation) Agency for Care Effectiveness Email: ACE_HTA@moh.gov.sg

In citation, please credit the Ministry of Health when you extract and use the information or data from the publication.